Basic Information
| LncRNA/CircRNA Name | GAS5 |
| Synonyms | NA |
| Region | GRCh38_1:173863900-173868882 |
| Ensemble | ENSG00000234741 |
| Refseq | NR_002578 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | apoptosis | Drug | Sorafenib | |
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | renal cell carcinoma |
| ICD-0-3 | C64.9 |
| Methods | qPCR, Western blot, Luciferase reporter assay, in vitro knockdown |
| Sample | renal cell carcinoma tissues, cell lines (OS-RC-2, Caki-2, Caki-1, A498, 786-O, ACHN, 769-P) |
| Expression Pattern | down-regulated |
| Function Description | GAS5 was downregulated in sorafenib nonresponsive RCCs. GAS5 overexpression conferred sorafenib sensitive to nonresponsive RCC cells, whereas knockdown of GAS5 promoted responsive RCC cells resistant to sorafenib treatment in vitro and in vivo. Mechanistically, GAS5 functioned as competing endogenous RNA to repress miR-21, which controlled its down-stream target SOX5. Caki-1 cells knock-downed GAS5 displayed an increasing proliferation ability to sorafenib treatment compared with the response of control cells. In addition, GAS5 knockdown decreased the sorafenib-induced cell apoptosis. |
| Pubmed ID | 29895198 |
| Year | 2018 |
| Title | Long Non-Coding RNA GAS5 Sensitizes Renal Cell Carcinoma to Sorafenib via miR-21/SOX5 Pathway |
External Links
| Links for GAS5 | GenBank HGNC NONCODE |
| Links for renal cell carcinoma | OMIM COSMIC |